Skip to main content
Premium Trial:

Request an Annual Quote

Evogene's Q2 Revenues Drop 9 Percent

NEW YORK (GenomeWeb) – Israel-based plant genetics firm Evogene today reported that its second quarter revenues declined 9 percent year over year, due to a sharp drop in revenues related to share purchases.

The firm posted total revenues of $3.9 million for the three months ended June 30, down from $4.3 million. Its revenue from research and development payments was $3.8 million, up from $3.5 million for Q2 2013, while its share purchase-related revenue was $83,000 versus $810,000. It noted that the share purchase-related revenue were the result of a required accounting treatment for past acquisitions of Evogene ordinary shares by Monsanto and Bayer.

Evogene's net loss climbed to $3.2 million, or $.13 per share, from $1.9 million, or $.10 per share.

The firm's R&D spending jumped 36 percent to $3.4 million from $2.5 million, while its business development costs rose to $562,000 from $305,000, and its general and administrative expenses nearly doubled to $1.2 million from $642,000.

As of June 30, Evogene had cash and cash equivalents of $8.7 million, marketable securities of $78.5 million, and short-term bank deposits totaling $24 million.

The company said that it anticipates its cash burn for the remainder of 2014 will be in the range of $15 million to $18 million.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.